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A B S T R A C T
The purpose of this study was to investigate a hypothesized correlation of development of a sensorineural hearing loss
and radiotherapy in patients with laryngeal and hypopharyngeal carcinoma. This prospective study included a total of
50 patients, which after strict exclusion critera (audiologic problems before RT, primary tumors of the auditory system,
spread of the primary tumor to any part of the auditory system) resulted in 23 analyzed patients, ranging between 50 and
76 years of age, with a mean age of 60. Audiometry measuring frequency-specific thresholds was performed in three time
points: one month before radiotherapy, one and six months after radiotherapy. A significant statistical difference in hear-
ing tresholds after radiotherapy was found in 6 out of 23 patients. An obvious tendency towards hearing loss without sta-
tistical significance at 250 and 4000 Hz was found for a whole tested population (p£0.3 with Bonferroni correction). Ob-
served tendency towards hearing loss after radiotherapy of laryngeal carcinoma was related to side of the tumor and less
severe when chemotherapy was not added as adjuvant therapy. These results should help to decrease a rate of hearing
loss by careful planing of ear protection, by using observed frequencies as relevant markers of hearing loss and by recon-
sidering adjuvant chemoterapy during radiotherapy of laryngeal carcinoma.
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Introduction
Treatment options for head and neck cancers depend
upon the size, location and spread of the tumor. Apart
from operative procedures, radiotherapy (RT) is a com-
monly used and often unavoidable method in the treat-
ment of nasopharyngeal, hypopharyngeal and laryngeal
carcinoma. Unfortunately, a complex anatomy and loca-
tion of a tumor often leads to exposure of external, mid-
dle and/or inner ear to radiation, which may consequent-
ly result in a conductive and/or sensorineural hearing
loss (SNHL)1,2.
Despite some already performed studies concerning
RT–induced ototoxicity in tumors of nasophyrnx/hypo-
pharynx3,4, a study focused on correlation of radiation
therapy of laryngeal carcinoma and hearing loss is miss-
ing in the literature. Moreover, we lack information
about possible correlation of dose, protocol for RT and
loss in particular frequencies.
The aim of this study was to focus on patients with la-
ryngeal carcinoma treated by adjuvant RT and to evalu-
ate the incidence of hearing loss after RT protocols for la-
ryngeal carcinoma. Using a spectrum of audiometric
parameters we showed that a dose and protocol used for
radiation therapy of laryngeal carcinoma leads to an ob-
vious tendency towards hearing impairment.
Materials and Methods
Patients
This study started with 50 patients collected in a pe-
riod from 2004 to 2008 at our Department. Exclusion cri-
teria which reduced our sample to 23 were as follows:
audiologic problems before RT, primary tumors of the au-
ditory system, spread of the primary tumor to any part of
945
Received for publication May 19, 2014
the auditory system, and the follow-up period less than 6
months. All patients were males ranging in age from 50
to 76 years with the median value of 60.
After surgical removal of the tumor, patients were
treated with 2D conventional radiotherapy by two lateral
opposed fields with a matching anterior lower neck por-
tal, with a 6 MeV electron beam (Mevatron X). The radia-
tion tumor dose was ranging from 50 to 64 Gy, depending
of size and location of tumor and status of regional lymph
nodes. The spinal cord and ears were shielded by addi-
tional 9–12 MeV electron beam. Patients were treated
with daily fractionation dose of 2 Gy. No other therapy
(e.g. chemotherapy) was included.
Hearing evaluation
Hearing evaluation was performed before, 1 month
after and 6 months after irradiation. In this way we
grouped our data in three dependant groups for statisti-
cal analyses. Audiological evaluation of bone conduction
at 250, 500, 1000, 2000, 4000 and 8000 Hz was used for
standard estimation of the cochlear damage degree.
Audiograms were performed for the right and left ear, in-
dependently of one another (Hortman AC 40). Measure-
ments were done before RT, at the end of treatment, and
2 to 6 months after radiotherapy. Pure tone thresholds
were investigated in a soundproof room by standard pro-
tocols. Clinically significant hearing loss was defined as
an increase of the hearing threshold of more than 15 dB
in two consecutive measurements conducted at least 6
months apart.
Patients which developed signs of conductive hearing
loss (e.g. otitis media) were excluded from this study.
Statistical analysis
Statistical analyses of the data were performed using
the IBM SPSS for Windows, version 20. The loss of hear-
ing in all frequencies was normally distributed according
to Kolmogorov-Smirnov test. The following parametric
test were used for clinical data: GLM Repeated Measures
analyzes of related dependent variables and the Paired-
-Samples T-test procedure for comparison the means of
two variables for a single group. Result are significant for
p£0.05, using Bonferoni correction and multiple compa-
ration.
Results
In order to analyse a hypothesized correlation be-
tween radiation therapy for carcinoma of larynx and
SNHL, we analyzed 23 patients in three time points: be-
fore, one month and six months after applied radiation
therapy. When compared before and one month after ra-
diation therapy, no single case of SNHL was found. How-
ever when the same patients were tested 6 months after
radiation therapy, SNHL was found in 6 out of 23 or 26%
of the patients (p£0.5) Four patients had bilateral hear-
ing loss, but the loss was more prominent on the side of
the lession. In two patients which exhibited unilateral
hearing loss, it was found on a side of tumor, i.e. on a side
where radiation therapy was primarily applied. Tables 1a
and 1b show the hearing threshold levels for the affected
and unaffected ears; hearing thresholds of the unaffected
and affected ear for three treatments of study group. An
obvious tendency towards significant hering loss was ob-
served at tumor side for frequencies 250 and 4000 Hz.
Presented data were divided into three groups: pretreat-
ment group before radiotherapy, posttreatment group
one month after radiotherapy, and posttreatment group
six months after radiotherapy. The mean threshold val-
ues were higher in both posttreatment groups for both
ears. When all 23 patients were fused, no statistical dif-
ference in hearing tresholds was observed. However an
obvious tendency towards hraing loss on a tumore side at
250 and 4000 Hz between pretreatment group and post-
treatment group six months after RT (Table 1a).
Discussion and Conclusion
To the best of our knowledge this is the first study
which analyzed hearing loss as a consequence of radia-
tion therapy without chemotherapy after treatment of
carcinoma of larynx. Carcinoma of larynx represents
around 5% of all tumors in human, but with incidence
steadily increasing and surprisingly, with unchanged or
even decreased survival rate in the last decades5. Thus
there is a need for improvement of current therapeutic
options and a tendency towards increased agresivness in
order to fight this tumor with generaly bad prognosis.
One of the most important therapeutic options for la-
ryngeal carcinoma is radiation therapy. Due to the high
tumor agresivness, a current protocol includes two lat-
eral opposed fields with a matching anterior lower neck
portal, with a 6 MeV electron beam (Mevatron X). The
radiation tumor dose is ranging from 50 to 64 Gy.
Side effects caused by radiation therapy in the region
of ears are manifested with skin fibrosis, nerve palsy and
two kinds of hearing impairment: conductive HL in outer
and middle ear or SNHL due to auditory nerve and co-
chlea damage6,7. When we analyzed 8 frequencies, rang-
ing between 250 and 8000 Hz, in three time points, be-
fore, one month and six months after of received radia-
tion therapy, it was obvious that in all frequencies there
was a trend towards increase of hearing tresholds trough
time. Nevertheless, two modalities of hearing impair-
ment were observed: one, in which increase in the treshold
was constant and another in which significant impair-
ment occurred between 1 and 6 months after received ra-
diation therapy. For example, a constant increase in
hearing treshold was observed in 250, 4000 and 8000 Hz
with a statistic significance reached in 250 and 4000 Hz.
On a contrary, on 1000, 1500 and 2000 Hz impairment
was observed only between 1st and 6th month after re-
ceived radiation therapy and a statistic significance was
reached only at 1000 Hz.
Up to now, several studies, mostly on patients with
nasopharyngeal carcinoma and few studies with mixed
laryngeal and nasoparyngeal tumor patients, in combi-
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nation with chemotherapy have been performed8–16. It
became obvious that hearing imparment is dependant on
location of the tumor and dose of radiation. In his pro-
spective study Liberman et al. reported a hearing loss fol-
lowed administration of RT and chemotherapy (cispla-
tin) in 36% (4/11) patients treated for laryngeal/ hypo-
pharyngeal carcinoma13. A higher incidence of SNHL in
Liberman study (36% vs. 23%) could be explained by ad-
ditional toxicity of chemotherapy used in combination
with RT. In a similar study Lacava et al. reported 43% of
patients with laryngeal carcinoma (treated by cisplatine)
experienced HL14. In this way, we can confirm that com-
bination of RT and chemoterapy in patients with laryn-
geal carcinoma brings significantly increased risk of hea-
ring impairment. The same findings were reporetd by
Chen3, Xiao4 and Hitchcock15 in nasopharyngeal carci-
noma treated by RT and chemotherapy.
The pathophysiological background of SNHL is only
partly explained. According to Low and Fong SNHL
mostly develops due to vascular effects, such as atrophy
of the stria vascularis of the cochlear duct17. Decreased
possibility for tissues regeneration is probably a reason
why SNHL is more likely to be completely irreversible in
older patients.
In conclusion, these results should help to decrease a
rate of hearing loss by careful planing of ear protection,
by using observed frequencies as relevant markers of
hearing loss and by reconsidering adjuvant chemoterapy
during radiotherapy of laryngeal carcinoma.
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TABLE 1B
HEARING THRESHOLDS OF THE AFFECTED EAR FOR A WHOLE GROUP IN THE THREE TIME POINTS.
Frequency
(Hz)




after 1 mont (2)
Posttreatment
after 6 months (3)
p* (1)-(3)
250 16.5±8.5 18.9±13.0 21.5±15.1 0.036
500 19.1±11.4 20.2±12.3 22.6±15.0 0.133
1000 22.4±14.4 21.7±13.1 25.4±16.1 0.110
1500 27.6±17.3 25.7±15.2 28.3±18.8 0.700
2000 33.3±21.2 31.5±18.9 34.3±23.2 0.636
3000 41.1±21.3 43.5±20.0 47.2±24.5 0.081
4000 54.1±21.1 58.3±23.8 61.7±25.8 0.033
8000 59.8±25.3 62.6±27.4 64.8±27.1 0.113
* t-test for dependent samples
TABLE 1A
HEARING THRESHOLDS OF THE UNAFFECTED EAR FOR A WHOLE GROUP IN THE THREE TIME POINTS.
Frequency
(Hz)




after 1 mont (2)
Posttreatment
after 6 months (3)
p* (1)-(3)
250 17.8±12.1 18.7±13.1 19.3±14.9 0.259
500 18.9±13.4 20.7±14.6 20.9±16.7 0.258
1000 22.8±13.6 23.7±16.7 23.7±17.4 0.755
1500 25.0±16.7 25.4±16.2 27.4±18.6 0,486
2000 27.2±19.8 28.5±16.1 31.5±22.1 0.278
3000 36.5±19.7 39.1±17.2 41.3±20.4 0.197
4000 50.2±21.7 51.1±19.9 54.8±20.1 0.250
8000 54.1±22.2 56.7±26.2 59.3±27.4 0.148
* t-test for dependent samples
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GUBITAK SLUHA UZROKOVAN RADIOTERAPIJOM U PACIJENATA S
LARINGEALNIM I HIPOFARINGEALNIM KARCINOMOM
S A @ E T A K
Cilj ove studije je bio sitra`iti pretpostavljenu vezu izme|u nastanka snzoneuralnog gubitka sluha i radioterapije u
pacijenata s laringealnim i hipofaringealnim karcinomom. Ova prospektivna studija je uklju~ila 50 pacijenata, koji su
nakon strogih kriterija eliminacije (audiolo{ki problemi prije radioterpaije, primarni tumor organa sluha, {irenje tu-
mora na organ sluha) svedeni na 23 analizirana pacijenta u dobi izme|u 50 i 76 godina (prosjek 60). Audimetrijska
mjerenja pragova po frekvencijama su ra|ena u tri vremenske to~ke: jedan mjesec prije radioterapije, jedan mjesec
nakon i {est mjeseci nakon radioterapije. Statisti~ki zna~ajan gubitak sluha je na|en u 6 od 23 pacijenta. O~igledna,
iako ne i statsti~ki zna~ajna tendencija gubitku sluha na frekvencijama od 250 i 4000 Hz je na|ena u cijeloj populaciji.
(p£0,3 bonferronijeva korekcija). Opa`en gubitak sluha nakon radioterapije laringealnog i hipofaringealnog karcinoma
se javio na strani tumora i zna~ajno manji u slu~aju kada nije kori{tena kemoterapija. Ovi rezultati mogu pomo}i da se
smanji gubitak sluha u navedenih pacijenata. To se mo`e posti}i boljom za{titom organa sluha tijekom radioterapije,
kori{tenjem opisanih frekvencija kao pouzdanih biljega gubitka sluha i kao izbjegavanjem dodatne kemoterapije tije-
kom radioterapije karcinoma larinsa i hipofarinksa.
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